Compositions and kits for treating influenza

Details Compositions and kits for treating influenza Compositions and kits for treating influenza

2011-07-19

2011-07-19

Olson, Eric S (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S629000, C514S043000, C514S659000, C514S661000, C514S662000, C514S459000, C514S563000, C536S028700, C549S424000, C560S128000, C562S507000, C564S456000, C564S458000, C564S459000

Reexamination Certificate

active

07981930

ABSTRACT:
Kits comprising an M2 inhibitor selected from amantadine and rimantadine; ribavirin, and a neuraminidase inhibitor (NAi) in an amount that is antivirally effective in the combination, an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin and a neuraminidase inhibitor are provided for the treatment of influenza. Some embodiments of the kits comprise an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin, and a neuraminidase inhibitor.

REFERENCES:
patent: 5360817 (1994-11-01), von Izstein et al.
patent: 5866601 (1999-02-01), Lew et al.
patent: 5916594 (1999-06-01), Liebowitz et al.
patent: 6605302 (2003-08-01), Faour et al.
patent: 7619007 (2009-11-01), Went et al.
patent: 2006/0008459 (2006-01-01), Johnson
patent: 2006/0035859 (2006-02-01), Carter et al.
patent: 2006/0247161 (2006-11-01), Planz et al.
patent: 2007/0270443 (2007-11-01), Went et al.
patent: 2008/0161324 (2008-07-01), Johansen et al.
patent: 2009/0247481 (2009-10-01), Nguyen et al.
patent: 01/45727 (2001-06-01), None
patent: WO 01/45727 (2002-06-01), None
patent: 2007/057436 (2007-05-01), None
patent: WO 2007/057436 (2007-07-01), None
Merriam-Webster's Collegiate Dictionary, Tenth Edition, published 1998 by Merriam-Webster, incorporated, pp. 924 and 935.
Drug labelling information for Symmatrel® (Amantadine Hydrochloride), approved Jul. 2002, pp. 1-12, downloaded from www.fda.gov.
Deltenre, et al. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol. Sep. 2004;41(3):462-73.
European search report and opinion dated Mar. 31, 2010 for Application No. 8732015.6.
Ilyushina, et al. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother. Nov. 2008;52(11):3889-97.
International search report dated Jun. 3, 2008 for PCT Application No. US2008/56678.
Jean, et al. Proteomic profiling of host cellular proteins incorporated by severe acute respiratory syndrome (SARS)—associated coronavirus virions: Insights into emerging virus biology and new therapeutics targets. Abstracts of the 19th International Conference on Antiviral Research (ICAR). Antiviral Res. May 2006;70(1):p. A29-A30, abstract No. 11.
Leophonte, P. Antivirals for influenza. Bull Acad Natl Med. Feb. 2005;189(2):341-55.
Nguyen, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One. Feb. 22, 2010;5(2):e9332.
Nguyen, et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother. Oct. 2009;53(10):4115-26.
Programs and Abstracts of the 19th International Conference on Antiviral Research (ICAR). San Juan, Puerto Rico. May 7-11, 2006.
Smee, et al. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother. May 2009;53(5):2120-8.
Nguyen et al., “Triple Combination of Amantadine, Ribavirin, and Osetamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Straing in Vitro,” PLoS One 5(2):1-12 (2010).
Nguyen et al., “Triple Comination of Oseltamivir, Amantadine, and Ribavirin Displays Synergistic Activity against Multiple Influenza Virus Strain in Vitro,” Antimicrobial Agents and Chemotherapy 53(10): 4115-4126 (2009).
Hoopes et al., “Evaluation of the Contribution of Amantadine, Ribavirin, and Oseltamivir in a Triple Combination Antiviral Drug (TCAD) Regimen to Suppressing the Emergence of Resistance Using a Novel Quantitative Approach,” Poster shown at 23rdICAR Meeting Apr. 25, 2010, http://isar.phrm.cf.ac.uk
ode/69.
Nguyen et al., “Triple Combination Antiviral Drug (TCAD) Regimen Composed of Amantadine, Ribavirin, and Oseltamivir Imposes a High Genetic Barrier tot he Development of Resistance against Influenza A Viruses in Vitro,” Poster shown at 23rdICAR Meeting, Apr. 25, 2020, http://isar.phrm.cf.ac.uk
ode/69.
Gross et al., “The Triple Combination Antiviral Drug (TCAD) Regimen of Amantadine, Ribavirin, and Oseltamivir is Highly Efficacious Against Susceptible and Resistant Influenza Virus Strains in Mouse Treatment Models,” Poster shown at 23rdICAR Meeting Apr. 25, 2010, http://isar.phrm.cf.ac.uk
ode/69.
Aoki, F.Y. et al., Early administration of oral oseltamivir increases the benefits of influenza treatment, J Antimicrob Chemother 2003, 51:123-29.
Burlington, D.B. et al., Anti-influenza A activity of combinations of amantadine and ribavirin in ferret tracheal ciliated epithelium, J Antimicrob Chemother 1983, 11:7-14.
Colgan, R. et al., Antiviral drugs in the immunocompetent host: part II. Treatment of influenza and respiratory syncytial virus infections, Am Pam Physician 2003, 67(4):763-6, 675 (abstract).
De Clercq, E., Antiviral agents active against influenza A viruses, Nature Reviews, Drug Discovery 2006, 5:1015-25.
De Clercq, E., Influenza virus inhibitors available for the chemotherapy and/or chemoprophylaxis of influenza virus infections, Verh K Acad Geneeskd Belg 2006, 68(2):121-37 (Abstract).
De Clercq., E. et al., Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention, Trends Pharmacol Sci 2007, 28(6):280-5.
De Jong, M.D., Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection, N Engl J Med 2005, 353:2667-72.
Galabov, A.S. et al., Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice, Antiviral Chem Chemother 2006, 17:251-8.
Galagov, G.A. et al., Combined action of ribovirin and rimantadine in experimental myxovirus infection, Experientia 1976, 33:905-6.
Govorkova, E.A. et al., Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells, Antimicrob Agents Chemother 2004, 48(12):4855-63.
Hayden, F.G. et al., Combined interferon-α2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro, Antimicrob Agents Chemother 1984, 25(1):53-7.
Hayden, F.G. et al., Combinations of antiviral agents for treatment of influenza virus infections, J Antimicrob Chemother 1986, 18(b): 177-83.
Hayden, F.G. et al., Enhancement of activity against influenza viruses by combinations of antiviral agents, Antimicrob Agents Chemother 1980, 18(4):536-41.
Hayden, F.G., Combination antiviral therapy for respiratory virus infections, Antiviral Res 1996, 29:45-8.
Hayden, F.G. et al., Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection, Aniviral Ther 1996, 1:51-6.
Ilyushina N.A., et al., Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza a variants, Antiviral Res 2006, 70:121-31.
Ilyushina, N.A. et al., Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice, Antiviral Ther 2007, 12:363-70.
Ison, M.G., et al., Therapeutic options for the management of influenza, Curr Opin Pharmacol 2001, 1:482-90.
Ison, M.G., et al., Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza, Antiviral Ther 2003, 8(3):183-90.
Leneva, I.A. et al., The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses, Antiviral Res 2000, 48:101-15.
Leophonte P., Antivirals for influenza, Bull Acad Natl Med 2005, 68(2):121-137.
Lipsitch et al., Antiviral resistance and the control of pandemic influenza, PLoS Med 2007, 4(1):e15. doi:10.1371/journal.pmed.0040015.
Madren, L.K. et al., In vitro inhibitory effects of combinations of anti-influenza agents Antiviral, Chem Chemother 1995, 6(2):109-13.
Masihi, K.N. et al., Low dose oral combination chemoprophylaxis with oseltamivir

Affiliated with

Also associated with

Rating

Compositions and kits for treating influenza does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and kits for treating influenza, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and kits for treating influenza will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2633329